{"id":"https://openalex.org/W3203178979","doi":"https://doi.org/10.1016/j.annonc.2021.08.353","title":"73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis","display_name":"73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis","publication_year":2021,"publication_date":"2021-09-01","ids":{"openalex":"https://openalex.org/W3203178979","doi":"https://doi.org/10.1016/j.annonc.2021.08.353","mag":"3203178979"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2021.08.353","doi":"https://doi.org/10.1016/j.annonc.2021.08.353","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.353","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)02582-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.annalsofoncology.org/article/S0923-7534(21)02582-5/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084909001","display_name":"Evan Y. Yu","orcid":"https://orcid.org/0000-0002-1510-8044","observed_orcids":["https://orcid.org/0000-0002-1510-8044"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Yu","raw_affiliation_strings":["Medicine, University of Washington, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine, University of Washington, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019869973","display_name":"Josep Maria Piulats","orcid":"https://orcid.org/0000-0002-3606-1724","observed_orcids":["https://orcid.org/0000-0002-3606-1724"]},"institutions":[{"id":"https://openalex.org/I4210107147","display_name":"Institut Catal\u00e0 d'Oncologia","ror":"https://ror.org/01j1eb875","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210107147"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J.M. Piulats","raw_affiliation_strings":["Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain","institution_ids":["https://openalex.org/I4210107147"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067036952","display_name":"Gw\u00e9na\u00eblle Gravis","orcid":"https://orcid.org/0000-0002-3127-1554","observed_orcids":["https://orcid.org/0000-0002-3127-1554"]},"institutions":[{"id":"https://openalex.org/I4210150365","display_name":"Institut Paoli-Calmettes","ror":"https://ror.org/04s3t1g37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"G. Gravis","raw_affiliation_strings":["Medical Oncology, Institut Paoli-Calmettes, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Institut Paoli-Calmettes, Paris, France","institution_ids":["https://openalex.org/I4210150365"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111319427","display_name":"P. Fong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801418622","display_name":"Auckland City Hospital","ror":"https://ror.org/05e8jge82","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I2801418622","https://openalex.org/I4405259026"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"P. Fong","raw_affiliation_strings":["Medical Oncology, Auckland City Hospital, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Auckland City Hospital, Auckland, New Zealand","institution_ids":["https://openalex.org/I2801418622"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072818969","display_name":"Tilman Todenh\u00f6fer","orcid":"https://orcid.org/0000-0003-4432-2741","observed_orcids":["https://orcid.org/0000-0003-4432-2741"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Todenh\u00f6fer","raw_affiliation_strings":["Clinical Trial Unit, Studienpraxis Urologie, N\u00fcrtingen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Trial Unit, Studienpraxis Urologie, N\u00fcrtingen, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021549650","display_name":"Brigitte Laguerre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110881","display_name":"Centre Eug\u00e8ne Marquis","ror":"https://ror.org/01yezas83","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210110881"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"B. Laguerre","raw_affiliation_strings":["Medical Oncology, Centre Eug\u00e8ne Marquis, Rennes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Centre Eug\u00e8ne Marquis, Rennes, France","institution_ids":["https://openalex.org/I4210110881"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005072118","display_name":"Jos\u00e9 \u00c1ngel Arranz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2960094004","display_name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n","ror":"https://ror.org/0111es613","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2960094004","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Arranz","raw_affiliation_strings":["Medical Oncology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain","institution_ids":["https://openalex.org/I2960094004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059690857","display_name":"St\u00e9phane Marie. Oudard","orcid":"https://orcid.org/0000-0003-0893-285X","observed_orcids":["https://orcid.org/0000-0003-0893-285X"]},"institutions":[{"id":"https://openalex.org/I4210102325","display_name":"H\u00f4pital Europ\u00e9en Georges-Pompidou","ror":"https://ror.org/016vx5156","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210102325","https://openalex.org/I4210120235"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"S. Oudard","raw_affiliation_strings":["Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France","institution_ids":["https://openalex.org/I4210102325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090082356","display_name":"Christophe Massard","orcid":"https://orcid.org/0000-0001-5505-0564","observed_orcids":["https://orcid.org/0000-0001-5505-0564"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4405269973","display_name":"Fondation Gustave Roussy","ror":"https://ror.org/05rfnt234","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405269973"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"C. Massard","raw_affiliation_strings":["Drug Development, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4405269973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005380574","display_name":"Michael St\u00f6eckle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Stoeckle","raw_affiliation_strings":["Urology, Universit\u00e4tskliniken des Saarlandes, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Urology, Universit\u00e4tskliniken des Saarlandes, Hamburg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015581478","display_name":"Luke T. Nordquist","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210107510","display_name":"Urology Cancer Center and GU Research Network","ror":"https://ror.org/01hyb7g80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210107510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L.T. Nordquist","raw_affiliation_strings":["Oncology, GU Research Network, Omaha, NE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, GU Research Network, Omaha, NE, USA","institution_ids":["https://openalex.org/I4210107510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001994148","display_name":"Joan Carles","orcid":"https://orcid.org/0000-0002-9983-5934","observed_orcids":["https://orcid.org/0000-0002-9983-5934"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"J. Carles","raw_affiliation_strings":["Medical Oncology, Vall d\u2019Hebron Institute of Oncology, Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology, Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079060977","display_name":"Min Huang","orcid":"https://orcid.org/0000-0003-1960-4552","observed_orcids":["https://orcid.org/0000-0003-1960-4552"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Huang","raw_affiliation_strings":["Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035071059","display_name":"Y. Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. Li","raw_affiliation_strings":["Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":null,"display_name":"P. Qiu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Qiu","raw_affiliation_strings":["Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018436364","display_name":"Christian Heinrich Poehlein","orcid":"https://orcid.org/0000-0002-3348-3059","observed_orcids":["https://orcid.org/0000-0002-3348-3059"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C.H. Poehlein","raw_affiliation_strings":["Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059978899","display_name":"Charles Schloss","orcid":"https://orcid.org/0000-0002-5106-3082","observed_orcids":["https://orcid.org/0000-0002-5106-3082"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Schloss","raw_affiliation_strings":["Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. de Bono","raw_affiliation_strings":["Clinical Studies, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Studies, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.7276,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.73102395,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":98},"biblio":{"volume":"32","issue":null,"first_page":"S387","last_page":"S387"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7621999979019165,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7621999979019165,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.23019999265670776,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/homologous-recombination-repair-mutations","display_name":"homologous recombination repair mutations","score":0.9580000042915344},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.9139999747276306},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9750000238418579},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":1.0},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.9520000219345093},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6729999780654907},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7960000038146973},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7820000052452087}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9090821146965027},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.89073646068573},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7493443489074707},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7033916711807251},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5973473191261292},{"id":"https://openalex.org/C102744134","wikidata":"https://www.wikidata.org/wiki/Q22280388","display_name":"Homologous recombination","level":3,"score":0.5376014113426208},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4767240583896637},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.4436016082763672},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4359470009803772},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3840551972389221},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.32201898097991943},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.1770395040512085},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.11774227023124695},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.11651837825775146},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.10900142788887024},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.06107598543167114},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2021.08.353","doi":"https://doi.org/10.1016/j.annonc.2021.08.353","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.353","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)02582-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2021.08.353","doi":"https://doi.org/10.1016/j.annonc.2021.08.353","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2021.08.353","pdf_url":"https://www.annalsofoncology.org/article/S0923-7534(21)02582-5/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8100000023841858,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307769","display_name":"Astellas Pharma US","ror":"https://ror.org/05pw69n24"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"},{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309470","display_name":"Meso Scale Diagnostics","ror":"https://ror.org/05jgy0m16"},{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"},{"id":"https://openalex.org/F4320315730","display_name":"Bayer Fund","ror":"https://ror.org/02c8q2v13"},{"id":"https://openalex.org/F4320316631","display_name":"Arog Pharmaceuticals","ror":"https://ror.org/01rgp0j22"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320318385","display_name":"Advanced Accelerator Applications","ror":null},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320327811","display_name":"PharmaMar","ror":"https://ror.org/02h694m69"},{"id":"https://openalex.org/F4320328455","display_name":"Ipsen","ror":"https://ror.org/00d801g55"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320337601","display_name":"Janssen Pharmaceuticals","ror":"https://ror.org/03qd7mz70"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3203178979.pdf","grobid_xml":"https://content.openalex.org/works/W3203178979.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7202356980","https://openalex.org/W4391303701","https://openalex.org/W4407699835","https://openalex.org/W4413024436","https://openalex.org/W7167915125","https://openalex.org/W7117769431","https://openalex.org/W4391302812","https://openalex.org/W4415899361","https://openalex.org/W7203662248","https://openalex.org/W3087970495"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":6}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2021-10-11T00:00:00"}